Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586629 | 0.86 | CA9 (0.54) | LMNAGAAMAPTCYP11B1CYP11B2 | |
| SCHEMBL2060589 | 0.83 | CA9 (0.44) | LMNAGAAMAPTCYP11B1CYP11B2 | |
| SCHEMBL30695802 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2CA9MEN1KMT2A | |
| SCHEMBL10916724 | 0.79 | CYP11B1 (0.51) | MAPTCYP11B1CYP11B2CA9RAB9A | |
| SCHEMBL13692913 | 0.79 | CYP11B1 (0.51) | MAPTCYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL31261247 | 0.79 | CYP11B1 (0.51) | MAPTCYP11B1CYP11B2CA9KMT2A | |
| SCHEMBL3597262 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2PDE3BPDE3AKCNH2 | |
| SCHEMBL787497 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2CA9MEN1KMT2A | |
| SCHEMBL434348 | 0.79 | CYP11B1 (0.51) | GAAMAPTCYP11B1CYP11B2CA9 | |
| SCHEMBL3068531 | 0.79 | AHR (0.56) | MAPTCYP11B1CYP11B2CA9PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022234271-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-11-10 | — | — | WO | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
| US-7354915-B2 | 6-amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070225281-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7247625-B2 | 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-07-24 | — | — | US | disclosed |
| WO-2007028445-A1 | 6-INDOLYL-4-YL-AMINO-5-HALOGENO-2-PYRIMIDINYL-AMINO DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028445-A1 | 6-INDOLYL-4-YL-AMINO-5-HALOGENO-2-PYRIMIDINYL-AMINO DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | WO | disclosed |
| US-20050085470-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH | 2005-04-21 | — | — | US | disclosed |
| US-4831027-A | USEFUL IN TREATMENT OF CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1989-05-16 | — | — | US | disclosed |
| EP-0263352-A1 | Imidazo-benzoxazinones, their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1988-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | LMNA 251/4885GAA 4641/4885MAPT 4758/4885 |
| US-20050085470-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | PGR, FSHR, GPR6 | LMNA 4353/4885GAA 4881/4885MAPT 4773/4885 |
| US-20070225281-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | PGR, FSHR, GPR6 | LMNA 4353/4885GAA 4881/4885MAPT 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.